BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
8/31/2021 6:51:25 AM | Browse: 369 | Download: 716
 |
Received |
|
2021-03-18 15:38 |
|
Peer-Review Started |
|
2021-03-18 15:42 |
 |
To Make the First Decision |
|
|
|
Return for Revision |
|
2021-04-23 18:33 |
|
Revised |
|
2021-05-03 17:44 |
|
Second Decision |
|
2021-07-14 03:31 |
|
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Executive Editor-in-Chief |
|
2021-07-14 07:06 |
|
Articles in Press |
|
2021-07-14 07:06 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
2021-07-25 23:11 |
|
Typeset the Manuscript |
|
2021-08-25 13:25 |
|
Publish the Manuscript Online |
|
2021-08-31 06:51 |
| ISSN |
2307-8960 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Infectious Diseases |
| Manuscript Type |
Retrospective Study |
| Article Title |
Efficacy evaluation of arbidol in COVID-19 patients: A retrospective study
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Shuo Wei, Sha Xu and Yun-Hu Pan |
| ORCID |
|
| Funding Agency and Grant Number |
| Funding Agency |
Grant Number |
| Fujian Medical University Sailing Fund |
2016QH121 |
|
| Corresponding Author |
Yun-Hu Pan, MD, Associate Chief Physician, Department of Respiratory Medicine, 907 Hospital of the Joint Logistics Team, No. 99 Binjiang North Road, Nanping 353000, Fujian Province, China. 18750975908@163.com |
| Key Words |
COVID-19; SARS-CoV-2; Arbidol; Treatment; Antiviral |
| Core Tip |
This study indicates the duration course of coronavirus disease 2019 (COVID-19) patients with moderate and severe cases was reduced by 6.183 days when arbidol was administered. Ferritin > 486.5 ng/mL and lactate dehydrogenase (LDH) > 239.5 U/L were independent risk factors for delayed recovery from COVID-19. Early administration of arbidol 200 mg administered orally t.i.d, with a 10-d course of treatment may be an effective management strategy in COVID-19 patients particularly those with increased serum ferritin or elevated LDH. |
| Publish Date |
2021-08-31 06:51 |
| Citation |
Wei S, Xu S, Pan YH. Efficacy evaluation of arbidol in COVID-19 patients: A retrospective study. World J Clin Cases 2021; 9(25): 7350-7357 |
| URL |
https://www.wjgnet.com/2307-8960/full/v9/i25/7350.htm |
| DOI |
https://dx.doi.org/10.12998/wjcc.v9.i25.7350 |
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
